Determining β-lactam exposure threshold to suppress resistance development in Gram-negative bacteria.

about

Optimizing β-lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective?

P2860

Q39344408-AB948AD1-6BB4-493C-B3CF-11D674C2CE52

P2860

Determining β-lactam exposure threshold to suppress resistance development in Gram-negative bacteria.

Item

http://www.wikidata.org/entity/Q40346786

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Determining β-lactam exposure ...... ent in Gram-negative bacteria.

@en

type

Item

label

Determining β-lactam exposure ...... ent in Gram-negative bacteria.

@en

prefLabel

Determining β-lactam exposure ...... ent in Gram-negative bacteria.

@en

P1476

Determining β-lactam exposure ...... ent in Gram-negative bacteria.

@en

P2093

Ana María Sánchez-Díaz

http://www.w3.org/2001/XMLSchema#string

Antonio Oliver

http://www.w3.org/2001/XMLSchema#string

Jian Zhou

http://www.w3.org/2001/XMLSchema#string

Kady Phe

http://www.w3.org/2001/XMLSchema#string

Kai-Tai Chang

http://www.w3.org/2001/XMLSchema#string

Kimberly R Ledesma

http://www.w3.org/2001/XMLSchema#string

Laura Zamorano

http://www.w3.org/2001/XMLSchema#string

Rafael Cantón

http://www.w3.org/2001/XMLSchema#string

Song Gao

http://www.w3.org/2001/XMLSchema#string

Vincent H Tam

http://www.w3.org/2001/XMLSchema#string

P2860

Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen

A novel approach to pharmacodynamic assessment of antimicrobial agents: new insights to dosing regimen design

Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.

Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa

Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections.

Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study.

Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections

Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model.

Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development.

Optimizing dosage to prevent emergence of resistance - lessons from in vitro models.

P304

1421-1428

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JAC/DKX001

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Françoise Van Bambeke

P577

2017-01-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28158470

http://www.w3.org/2001/XMLSchema#string

P921

Gram-negative bacteria

Determining β-lactam exposure threshold to suppress resistance development in Gram-negative bacteria.

about

P2860

P2860

Determining β-lactam exposure threshold to suppress resistance development in Gram-negative bacteria.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921